U.S. FDA Approved Drugs from 2015-June 2020: A Perspective
No Thumbnail Available
Date
2021-02-22T00:00:00
Journal Title
Journal ISSN
Volume Title
Publisher
American Chemical Society
Abstract
In the present work, we report compilation and analysis of 245 drugs, including small and macromolecules approved by the U.S. FDA from 2015 until June 2020. Nearly 29% of the drugs were approved for the treatment of various types of cancers. Other major therapeutic areas of focus were infectious diseases (14%); neurological conditions (12%); and genetic, metabolic, and cardiovascular disorders (7-8% each). Itemization of the approved drugs according to the year of approval, sponsor, target, chemical class, major drug-metabolizing enzyme(s), route of administration/elimination, and drug-drug interaction liability (perpetrator or/and victim) is presented and discussed. An effort has been made to analyze the pharmacophores to identify the structural (e.g., aromatic, heterocycle, and aliphatic), elemental (e.g., boron, sulfur, fluorine, phosphorus, and deuterium), and functional group (e.g., nitro drugs) diversity among the approved drugs. Further, descriptor-based chemical space analysis of FDA approved drugs and several strategies utilized for optimizing metabolism leading to their discoveries have been emphasized. Finally, an analysis of drug-likeness for the approved drugs is presented. � 2021 American Chemical Society.
Description
Keywords
Drug Approval, Humans, Organic Chemicals, United States, United States Food and Drug Administration, agents acting on the genital system, agents acting on the peripheral nervous and neuromuscular systems, agents affecting metabolism, antibody drug conjugate, antiinfective agent, antineoplastic agent, biologic factors and agents acting on the immune system, boron, cardiovascular agent, central nervous system agents, dermatological agent, deuterium, diagnostic agent, drug metabolizing enzyme, fluorine, functional group, gastrointestinal agent, miscellaneous drugs and agents, nutrition supplement, phosphorus, respiratory tract agent, sulfur, organic compound, autoimmune disease, cardiovascular disease, drug approval, drug indication, drug interaction, drug metabolism, drug structure, Food and Drug Administration, gastrointestinal disease, genetic disorder, infection, macromolecule, malignant neoplasm, metabolic disorder, neurologic disease, ophthalmology, pharmacophore, respiratory tract disease, Review, United States, chemistry, human